AutoImmune-AIMM Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AutoImmune-AIMM

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Joe who wrote (193)	8/5/1997 10:40:00 AM
From: Dr. John M. de Castro	of 298

The diabetes program is viable and partnered. The market is completely discounting this program because of the failures of MYLORAL and COLORAL. Basically, the market doesn't believe in the oral tolerance technology anymore. However, you are absolutely right. Should oral tolerance work for diabetes, it would be a major breakthrough for AIMM and the stock would rocket. There are no data to suggest that this program will or will not work. There are Phase II clinical trials currently underway. The results of these trials should indicate whether this program is viable. Does anyone know when results are expected from these trials? John de C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next